Menu Search
Equities

BridgeBio Pharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2CL:DUS

BridgeBio Pharma Inc

Actions
  • Price (EUR)59.50
  • Today's Change0.84 / 1.43%
  • Shares traded70.00
  • 1 Year change+93.43%
  • Beta--
Data delayed at least 15 minutes, as of Feb 09 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

  • Revenue in USD (TTM)353.78m
  • Net income in USD-797.12m
  • Incorporated2019
  • Employees725.00
  • Location
    BridgeBio Pharma Inc3160 Porter Dr., Suite 250PALO ALTO 94304United StatesUSA
  • Phone+1 (650) 391-9740
  • Fax+1 (302) 655-5049
  • Websitehttps://bridgebio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.